# Vazyme Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vazyme-biotech-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.vazyme.com
- Total disclosed funding: $80M
- Latest round: Series C (May 8, 2020)
- Investors on record: 8

## About

Based in nanjing, China, and established in 2012, Vazyme Biotech Co.,Ltd. is a biotech company that focuses on R&D of biological reagents, in vitro diagnostic reagents, and antibody drugs. The company has more than 400 R&D team members who developed more than 200 genetic engineering recombinases, more than 1,000 antigens and monoclonal antibodies, and more than 500 end products. The company has built point-of-care testing (POCT) product line. The biological reagents served for more than 1,000 research institutions, more than 1600 companies. Besides, it's in vitro diagnostic reagents served more than 2,200 healthcare institutions. Up to June 2021, it has 50 patents, and 67 medical device registration certificates. It has won many honors, including Postdoctoral Innovation Practice Base of Jiangsu Province, Jiangsu Science and Technology Little Giant Enterprise.

The company provides biological reagents, in vitro diagnostic reagents, and antibody drugs. The biological reagents are more than 500, divided into many series, such as polymerase chain reaction (PCR) series, qPCR series, molecular cloning, gene sequencing, which used in the field of scientific research, high-throughput sequencing, and vaccine research and development. The in vitro diagnostic reagents has eight products series, including cardio-cerbral blood vessel, prenatal and postnatal care, and stomach function. 

The company plans to build research and development base, and expand marketing network.

## Funding rounds

- Series C, May 8, 2020, $78M — China Life Capital, Sherpa Healthcare Partners
- Series B, Apr 17, 2019 — Everest VC, Huatai Health Fund
- Series B, Aug 22, 2018, $1.8M — Everest VC
- Series A, Dec 16, 2016 — Share Capital, GF Xinde Investment, Shang Finance
- Angel, Mar 1, 2013 — Danen Capital

## Investors

- Danen Capital (https://capitalatlas.ai/funds/danen-capital) — Angel
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- Shang Finance (https://capitalatlas.ai/funds/shang-finance) — Series A
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series B
- Huatai Health Fund — Series B
- China Life Capital — Series C
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series C